[{"id":"b4dc606c-2518-4a70-8ed6-be2729cbf916","acronym":"","url":"https://clinicaltrials.gov/study/NCT01938846","created_at":"2021-01-18T08:46:34.773Z","updated_at":"2024-07-02T16:37:04.225Z","phase":"Phase 1","brief_title":"BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors","source_id_and_acronym":"NCT01938846","lead_sponsor":"Boehringer Ingelheim","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • exemestane • XP-105"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 09/05/2013","start_date":" 09/05/2013","primary_txt":" Primary completion: 07/30/2016","primary_completion_date":" 07/30/2016","study_txt":" Completion: 06/22/2017","study_completion_date":" 06/22/2017","last_update_posted":"2019-01-04"}]